DIA
Drug Information Association Logo
« Back to Listing

Collaboration in R&D: What’s New for TransCelerate BioPharma?

Track:
Clinical Operations

Day & Time:
June 17, 8:00AM - 9:30AM (Pacific Standard Time)

Session Number:
202

Room Number:
2

Level:
Intermediate

Type:
Forum

Title:
Collaboration in R&D: What’s New for TransCelerate BioPharma?

Chair(s):
Susan Cantrell, RPh
Senior Vice President and Managing Director, DIA Americas
DIA, United States

Description:
This forum will provide highlights and accomplishments from the original five TransCelerate initiatives – development of a standardized approach for risk-based site monitoring, mutual recognition of clinical trial site qualification and training, development of clinical data standards, establishment of a comparator drug network and development of a shared investigator site portal, as well as discuss current progress of new initiatives and line extensions in 2014, including creation of common clinical trial protocol templates, development of a special populations (pediatric and minority) clinical trial network and establishment of a shared investigator registry. There will also be Q&A with the panel, which will include members of TransCelerate’s Board of Directors and Operations Committee.

Learning Objective(s):
Discuss accomplishments to date for the TransCelerate initiatives; Describe the progress of new initiatives and line extensions in 2014.

Presentation(s) & Speaker(s):
Panelist
Dalvir Gill, PhD
Chief Executive Officer
TransCelerate Biopharma Inc, United States

Panelist
John W. Hubbard, PhD
Senior Vice President and Worldwide Head of Development Operations
Pfizer Inc, United States

Panelist
Lynn G. Marks, MD
Senior Vice President, Projects, Clinical Platforms and Sciences
GlaxoSmithKline, United States